Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,4-Dihydro‐2′‐deoxyuridine‐5′‐monophosphate is a synthetic or experimental nucleoside monophosphate analog belonging to the class of pentose phosphates and pyrimidine deoxyribonucleotides. It is structurally related to deoxyuridine monophosphate (dUMP), but features a saturated (dihydrouracil) base. The compound has not been approved for clinical use and is primarily used in research settings as a biochemical tool or substrate analog. Its mechanism of action would be expected to involve incorporation into DNA or interaction with enzymes involved in nucleotide metabolism; however specific pharmacological activity and indications are not established[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,4-dihydro-2'-deoxyuridine-5'-monophosphate.